GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million in cash, adding U.S. radiopharmaceutical manufacturing and distribution capabilities to its Pharmaceutical Diagnostics business. The transaction would give GE HealthCare a broader domestic network of specialized facilities serving the PET radiopharmaceutical supply chain.
Key Takeaways
- GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash
- SOFIE operates 15 contract manufacturing sites across the United States
- SOFIE’s U.S. manufacturing network includes 21 cyclotrons
- The acquisition would expand GE HealthCare’s domestic radiopharmaceutical capabilities
- GE HealthCare expects the transaction to close in the first half of 2027, subject to required conditions and regulatory approvals
GE HealthCare Agrees to Acquire SOFIE Biosciences
GE HealthCare has agreed to acquire SOFIE Biosciences in a $945 million cash transaction that would add SOFIE’s U.S. radiopharmaceutical manufacturing and distribution network to GE HealthCare’s Pharmaceutical Diagnostics business.
The transaction is focused on capabilities supporting the PET radiopharmaceutical supply chain. Rather than adding only a product line, GE HealthCare would gain an established network of specialized facilities and manufacturing infrastructure.
SOFIE operates 15 contract manufacturing sites across the United States, giving the acquisition a significant domestic production component. Its network also includes 21 cyclotrons used as part of radiopharmaceutical manufacturing operations.
The acquisition would integrate those existing assets into GE HealthCare’s broader Pharmaceutical Diagnostics activities instead of requiring the company to build comparable infrastructure from the ground up.
GE HealthCare expects the transaction to close in the first half of 2027, subject to regulatory approvals and other required closing conditions.
$945 Million Deal Expands Radiopharmaceutical Capabilities
The $945 million acquisition would expand GE HealthCare’s U.S. manufacturing footprint through SOFIE’s existing facilities and specialized production equipment.
The deal comes as the pharmaceutical industry places greater emphasis on domestic pharmaceutical production, with drugmakers increasingly considering U.S.-based manufacturing capacity and supply-chain resilience.
SOFIE’s network includes 15 contract manufacturing sites and 21 cyclotrons. Cyclotrons are specialized equipment used in the production of certain radiopharmaceutical materials.
The acquired infrastructure would support activities connected to positron emission tomography, or PET, which uses radiopharmaceuticals as part of diagnostic imaging procedures.
For GE HealthCare, the transaction would provide additional manufacturing and distribution capacity within an area already connected to its Pharmaceutical Diagnostics business.
The cash consideration establishes a $945 million value for the acquisition, although ownership will not transfer until the required closing conditions have been satisfied.
SOFIE Adds U.S. Manufacturing and Distribution Facilities
SOFIE’s domestic manufacturing network is a central part of the acquisition. Its 15 contract manufacturing locations would give GE HealthCare an established footprint across multiple U.S. facilities.
The 21 cyclotrons within the network add specialized production infrastructure to those operations. Together, the sites and equipment support SOFIE’s role within the PET radiopharmaceutical supply chain.
The acquisition would also broaden GE HealthCare’s distribution capabilities. Radiopharmaceutical operations require both specialized production and an infrastructure capable of supporting the movement of products through the supply chain.
SOFIE’s existing network gives GE HealthCare a way to expand those capabilities through acquisition rather than developing an equivalent national footprint independently.
That distinction makes the physical infrastructure one of the most significant operational elements of the transaction.
Domestic Manufacturing Becomes a Larger Strategic Focus
The acquisition also fits within a broader shift toward expanding manufacturing capacity inside the United States.
Industries including pharmaceuticals have been part of wider manufacturing reshoring efforts aimed at bringing production closer to domestic customers and reducing dependence on overseas supply chains.
For GE HealthCare, SOFIE’s existing U.S. facilities provide an immediate domestic network if the acquisition closes. The transaction would add operating sites rather than relying solely on future facility construction.
The domestic footprint is particularly relevant because SOFIE’s assets are spread across multiple contract manufacturing locations rather than concentrated in a single facility.
That network would give GE HealthCare additional infrastructure for manufacturing and distributing radiopharmaceuticals within the United States.
Acquisition Expands GE HealthCare’s Pharmaceutical Diagnostics Business
SOFIE would become part of GE HealthCare’s Pharmaceutical Diagnostics business following completion of the acquisition.
The transaction would broaden that business through additional manufacturing, distribution and PET radiopharmaceutical capabilities.
SOFIE’s sites and cyclotrons form the principal operating assets involved in the expansion. Their addition would increase the physical infrastructure available to GE HealthCare for U.S. radiopharmaceutical activities.
The transaction therefore combines financial and operational elements. The $945 million cash price defines the acquisition value, while the manufacturing sites, cyclotrons and distribution capabilities represent the assets being added.
Integrating those operations would expand GE HealthCare’s domestic presence within the specialized supply chain supporting PET imaging.
Transaction Expected to Close in First Half of 2027
GE HealthCare expects the acquisition of SOFIE Biosciences to close in the first half of 2027.
Completion remains subject to required conditions and regulatory approvals. Until those requirements are satisfied, SOFIE will continue to operate separately from GE HealthCare.
If completed, the transaction would bring SOFIE’s 15 U.S. contract manufacturing sites and network of 21 cyclotrons into GE HealthCare’s Pharmaceutical Diagnostics business.
The deal would also expand GE HealthCare’s domestic radiopharmaceutical manufacturing and distribution capabilities, with the acquired operations focused on supporting the PET radiopharmaceutical supply chain.
The first-half 2027 target therefore represents the expected completion window rather than a guaranteed closing date.
Frequently Asked Questions
What is GE HealthCare acquiring from SOFIE Biosciences?
GE HealthCare has agreed to acquire SOFIE Biosciences, including its U.S. radiopharmaceutical manufacturing and distribution operations. SOFIE operates 15 contract manufacturing sites and a network of 21 cyclotrons.
How much is GE HealthCare paying for SOFIE Biosciences?
GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash.
How many U.S. facilities does SOFIE operate?
SOFIE operates 15 contract manufacturing sites across the United States. Its U.S. network also includes 21 cyclotrons.
What does the acquisition add to GE HealthCare’s business?
The transaction would add domestic radiopharmaceutical manufacturing and distribution capabilities to GE HealthCare’s Pharmaceutical Diagnostics business, with a focus on the PET radiopharmaceutical supply chain.
When is the GE HealthCare and SOFIE transaction expected to close?
GE HealthCare expects the transaction to close in the first half of 2027, subject to required closing conditions and regulatory approvals.
